

## Contact

Merck KGaA, Darmstadt, Germany  
Investor Relations  
Frankfurter Strasse 250  
64293 Darmstadt  
Germany  
Phone: +49 6151 72 3321  
e-mail: [investor.relations@merckgroup.com](mailto:investor.relations@merckgroup.com)  
[www.merckgroup.com](http://www.merckgroup.com)

WKN: 659990  
ISIN: DE0006599905  
Ticker Symbol: MRK

# Financial Statements Q1 2019 – Q4 2020

## Content

---

### 1 Income statements

- 1.1 Group, quarterly
- 1.2 Healthcare, quarterly
- 1.3 Life Science, quarterly
- 1.4 Performance Materials, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

### 2 Cash flow statement

### 3 Balance sheet

**EBITDA pre Merck KGaA, Darmstadt, Germany**

€ million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Healthcare	332.0	527.8	859.8	500.8	1 360.6	561.1	1 061.9	1 921.7	472.1	374.0	846.2	896.0	1 742.1	525.1	1 421.1	2 267.3	42.2%	-29.1%	-1.6%	78.9%	28.0%	-6.4%	33.8%	18.0%
in % of net sales	22.4%	31.5%	27.2%	28.5%	27.7%	31.2%	29.9%	28.6%	27.8%	24.9%	26.4%	52.7%	35.5%	30.2%	41.3%	34.1%								
Life Science	515.7	533.3	1 049.0	531.1	1 580.1	548.7	1 079.8	2 128.9	552.7	569.0	1 121.8	630.2	1 752.0	653.1	1 283.3	2 405.0	7.2%	6.7%	6.9%	18.7%	10.9%	19.0%	18.8%	13.0%
in % of net sales	31.0%	31.3%	31.2%	31.0%	31.1%	30.8%	30.9%	31.0%	31.2%	31.5%	31.4%	33.0%	31.9%	32.2%	32.6%	32.0%								
Performance Materials	192.6	190.3	382.9	177.5	560.4	243.0	420.5	803.4	285.5	238.3	523.8	254.2	778.0	246.1	500.4	1 024.2	48.3%	25.2%	36.8%	43.3%	38.8%	1.3%	19.0%	27.5%
in % of net sales	31.9%	32.3%	32.1%	30.5%	31.6%	30.5%	30.5%	31.2%	31.7%	29.3%	30.6%	30.4%	30.5%	29.6%	30.0%	30.3%								
Corporate/Others	-111.8	-112.1	-223.9	-98.1	-322.0	-147.2	-245.3	-469.2	-129.1	-107.2	-236.2	-79.7	-315.9	-179.1	-258.8	-495.1	15.5%	-4.5%	5.5%	-18.7%	-1.9%	21.7%	5.5%	5.5%
<b>Group</b>	<b>928.5</b>	<b>1 139.3</b>	<b>2 067.8</b>	<b>1 111.3</b>	<b>3 179.1</b>	<b>1 205.7</b>	<b>2 316.9</b>	<b>4 384.8</b>	<b>1 181.3</b>	<b>1 074.2</b>	<b>2 255.5</b>	<b>1 700.7</b>	<b>3 956.2</b>	<b>1 245.2</b>	<b>2 945.9</b>	<b>5 201.4</b>	<b>27.2%</b>	<b>-5.7%</b>	<b>9.1%</b>	<b>53.0%</b>	<b>24.4%</b>	<b>3.3%</b>	<b>27.1%</b>	<b>18.6%</b>
in % of net sales	24.8%	28.7%	26.8%	27.4%	27.0%	27.5%	27.5%	27.1%	27.0%	26.1%	26.6%	38.2%	30.6%	27.1%	32.6%	29.7%								

Sum of items may not foot due to rounding.









Detailed reconciliation - Healthcare

€ million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>127.8</b>	<b>345.1</b>	<b>472.9</b>	<b>325.4</b>	<b>798.2</b>	<b>351.2</b>	<b>676.6</b>	<b>1 149.5</b>	<b>422.3</b>	<b>269.2</b>	<b>691.5</b>	<b>807.4</b>	<b>1 498.9</b>	<b>304.9</b>	<b>1 112.3</b>	<b>1 803.8</b>	<b>230.5%</b>	<b>-22.0%</b>	<b>46.2%</b>	<b>148.1%</b>	<b>87.8%</b>	<b>-13.2%</b>	<b>64.4%</b>	<b>56.9%</b>
Regular depreciation and amortization*	60.8	63.9	124.6	65.0	188.7	70.9	135.9	260.6	66.8	62.7	129.5	71.5	201.0	71.5	143.0	272.5	9.9%	-1.8%	3.9%	10.0%	6.5%	0.8%	5.2%	4.6%
<b>Impairments not adjusted</b>	<b>27.2</b>	<b>0.2</b>	<b>27.4</b>	<b>0.0</b>	<b>28.3</b>	<b>5.2</b>	<b>5.2</b>	<b>32.5</b>	<b>0.0</b>	<b>11.0</b>	<b>11.0</b>	<b>0.0</b>	<b>11.0</b>	<b>43.4</b>	<b>43.4</b>	<b>54.4</b>	<b>-100.0%</b>	<b>&gt;1.000%</b>	<b>-59.8%</b>	<b>408.6%</b>	<b>-61.1%</b>	<b>740.9%</b>	<b>740.9%</b>	<b>67.1%</b>
Amortization of purchased intangible assets	113.3	113.4	226.7	113.2	339.8	112.9	226.0	452.7	10.1	16.0	26.1	12.9	39.0	12.8	25.7	51.8	-91.1%	-85.9%	-88.5%	-88.6%	-88.5%	-88.7%	-88.6%	-88.6%
Impairments**	0.0	0.0	0.0	0.0	0.0	1.1	1.1	1.1	1.9	0.0	1.9	0.0	1.9	0.2	0.2	2.0	n.m.	n.m.	n.m.	n.m.	n.m.	-83.9%	-83.9%	88.3%
<b>Total depreciation and amortization</b>	<b>201.3</b>	<b>177.4</b>	<b>378.7</b>	<b>178.2</b>	<b>556.9</b>	<b>190.0</b>	<b>368.2</b>	<b>746.9</b>	<b>78.8</b>	<b>89.7</b>	<b>168.5</b>	<b>84.4</b>	<b>252.9</b>	<b>127.8</b>	<b>212.2</b>	<b>380.7</b>	<b>-60.9%</b>	<b>-49.4%</b>	<b>-55.5%</b>	<b>-52.6%</b>	<b>-54.6%</b>	<b>-32.7%</b>	<b>-42.4%</b>	<b>-49.0%</b>
<b>EBITDA</b>	<b>329.1</b>	<b>522.5</b>	<b>851.6</b>	<b>503.5</b>	<b>1 355.1</b>	<b>541.2</b>	<b>1 044.8</b>	<b>1 896.4</b>	<b>501.0</b>	<b>359.0</b>	<b>860.0</b>	<b>891.8</b>	<b>1 751.8</b>	<b>432.7</b>	<b>1 324.5</b>	<b>2 184.5</b>	<b>52.3%</b>	<b>-31.3%</b>	<b>1.0%</b>	<b>77.1%</b>	<b>29.3%</b>	<b>-20.1%</b>	<b>26.8%</b>	<b>15.2%</b>
<b>Adjustments</b>																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs																								
Restructuring costs	0.1	4.7	4.8	1.5	6.3	10.7	12.2	17.0	2.0	12.4	14.4	4.7	19.1	75.7	80.4	94.8	>1.000%	166.0%	199.5%	216.3%	203.5%	607.3%	559.4%	457.6%
<b>Total</b>	<b>0.1</b>	<b>4.7</b>	<b>4.8</b>	<b>1.5</b>	<b>6.3</b>	<b>10.7</b>	<b>12.2</b>	<b>17.0</b>	<b>2.0</b>	<b>12.4</b>	<b>14.4</b>	<b>4.7</b>	<b>19.1</b>	<b>75.7</b>	<b>80.4</b>	<b>94.8</b>	>1.000%	166.0%	199.5%	216.3%	203.5%	607.3%	559.4%	457.6%
Integration costs/IT costs																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ERP/HR systems	1.9	3.6	5.4	2.1	7.5	5.3	7.4	12.8	0.9	1.3	2.2	0.2	2.4	1.9	2.0	4.2	-50.9%	-63.7%	-59.3%	-92.8%	-68.6%	-64.8%	-72.7%	-67.0%
<b>Total</b>	<b>1.9</b>	<b>3.6</b>	<b>5.4</b>	<b>2.1</b>	<b>7.5</b>	<b>5.3</b>	<b>7.4</b>	<b>12.8</b>	<b>0.9</b>	<b>1.3</b>	<b>2.2</b>	<b>0.2</b>	<b>2.4</b>	<b>1.9</b>	<b>2.0</b>	<b>4.2</b>	-50.9%	-63.7%	-59.3%	-92.8%	-68.6%	-64.8%	-72.7%	-67.0%
Gain (-)/losses (+) on the divestment of businesses																								
Sale of Kuvan and Biosimilars	0.0	-4.9	-4.8	0.0	-4.8	1.0	1.0	-3.8	0.1	-1.7	-1.7	0.0	-1.6	10.6	10.6	9.0	43.5%	-64.8%	-65.8%	213.0%	-66.3%	>1.000%	>1.000%	n.m.
Sale of Consumer Health	0.8	1.9	2.7	-6.4	-3.7	2.9	-3.5	-0.8	4.6	3.0	7.7	0.9	8.5	1.3	2.2	9.8	494.6%	57.1%	183.7%	n.m.	n.m.	-55.2%	n.m.	n.m.
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-36.5	0.1	-36.5	-1.8	-38.2	3.8	2.0	-34.5	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Others	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1	0.0	0.0	0.0	0.2	0.2	-0.7	-0.5	-0.5	-100.0%	>1.000%	n.m.	n.m.	n.m.	725.7%	515.4%	468.6%
<b>Total</b>	<b>0.8</b>	<b>-3.0</b>	<b>-2.1</b>	<b>-6.4</b>	<b>-8.5</b>	<b>4.0</b>	<b>-2.4</b>	<b>-4.5</b>	<b>-31.8</b>	<b>1.4</b>	<b>-30.4</b>	<b>-0.7</b>	<b>-31.1</b>	<b>14.9</b>	<b>14.2</b>	<b>-16.2</b>	n.m.	n.m.	>1.000%	-89.3%	266.8%	274.9%	n.m.	259.6%
Other one-time costs																								
Others	0.1	0.1	0.1	0.0	0.1	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
<b>Total</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.0</b>	<b>0.1</b>	<b>-0.1</b>	<b>-0.1</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
<b>Total adjustments</b>	<b>2.9</b>	<b>5.3</b>	<b>8.2</b>	<b>-2.8</b>	<b>5.5</b>	<b>19.9</b>	<b>17.1</b>	<b>25.4</b>	<b>-28.9</b>	<b>15.1</b>	<b>-13.8</b>	<b>4.2</b>	<b>-9.6</b>	<b>92.4</b>	<b>96.6</b>	<b>82.8</b>	n.m.	183.3%	n.m.	n.m.	n.m.	364.9%	465.0%	226.7%
<b>EBITDA pre</b>	<b>332.0</b>	<b>527.8</b>	<b>859.8</b>	<b>500.8</b>	<b>1 360.6</b>	<b>561.1</b>	<b>1 061.9</b>	<b>1 921.7</b>	<b>472.1</b>	<b>374.0</b>	<b>846.2</b>	<b>896.0</b>	<b>1 742.1</b>	<b>525.1</b>	<b>1 421.1</b>	<b>2 267.3</b>	42.2%	-29.1%	-1.6%	78.9%	28.0%	-6.4%	33.8%	18.0%

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.



Detailed reconciliation - Life Science

€ million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	313.4	321.7	635.1	316.0	951.1	329.3	645.3	1 280.4	345.3	385.6	730.9	416.8	1 147.6	451.0	867.8	1 598.6	10.2%	19.9%	15.1%	31.9%	20.7%	36.9%	34.5%	24.9%
Regular depreciation and amortization*	71.4	72.8	144.2	76.8	221.0	86.2	162.9	307.1	77.1	79.3	156.4	82.0	238.5	84.5	166.6	323.0	8.0%	8.9%	8.5%	6.9%	7.9%	-1.9%	2.2%	5.2%
Amortization of purchased intangible assets	122.0	123.8	245.8	118.0	363.9	118.2	236.2	482.1	118.9	119.5	238.4	112.9	351.4	111.5	224.5	462.9	-2.6%	-3.5%	-3.0%	-4.3%	-3.4%	-5.6%	-5.0%	-4.0%
Impairments**	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	2.7	2.7	2.7	-100.0%	-100.0%	-100.0%	-100.0%	>1.000%	>1.000%	>1.000%	>1.000%
<b>Total depreciation and amortization</b>	193.5	196.6	390.1	194.9	584.9	204.4	399.2	789.3	196.0	198.8	394.8	195.0	589.8	198.7	393.7	788.5	1.3%	1.1%	1.2%	0.1%	0.8%	-2.8%	-1.4%	-0.1%
<b>EBITDA</b>	506.8	518.3	1 025.1	510.9	1 536.0	533.7	1 044.6	2 069.7	541.3	584.4	1 125.7	611.7	1 737.4	649.7	1 261.5	2 387.2	6.8%	12.8%	9.8%	19.7%	13.1%	21.7%	20.8%	15.3%
<b>Adjustments</b>																								
<b>Acquisition costs</b>	0.2	0.2	0.4	0.1	0.4	1.6	1.7	2.0	0.0	-30.0	-30.0	-0.1	-30.1	0.0	-0.1	-30.1	-85.7%	n.m.						
<b>Restructuring costs</b>																								
Restructuring costs	1.1	3.8	4.9	6.1	11.0	1.5	7.6	12.5	1.7	1.0	2.8	11.4	14.1	1.7	13.1	15.9	53.2%	-72.5%	-43.3%	87.4%	28.9%	13.1%	72.4%	27.0%
<b>Total</b>	1.1	3.8	4.9	6.1	11.0	1.5	7.6	12.5	1.7	1.0	2.8	11.4	14.1	1.7	13.1	15.9	53.2%	-72.5%	-43.3%	87.4%	28.9%	13.1%	72.4%	27.0%
<b>Integration costs/IT costs</b>																								
Integration Cost	0.6	1.0	1.5	0.8	2.3	0.2	1.0	2.5	0.8	1.5	2.3	0.0	2.3	0.9	0.8	3.2	44.9%	53.7%	50.4%	n.m.	-1.0%	286.5%	-14.9%	24.8%
ERP/HR systems	6.0	8.8	14.8	11.2	26.0	7.1	18.3	33.1	8.8	12.1	20.9	7.2	28.1	0.8	8.0	28.9	46.1%	38.0%	41.3%	-35.5%	8.2%	-89.4%	-56.4%	-12.8%
<b>Total</b>	6.6	9.7	16.3	12.0	28.3	7.3	19.3	35.7	9.7	13.6	23.2	7.2	30.4	1.6	8.8	32.1	46.0%	39.5%	42.1%	-39.9%	7.4%	-77.7%	-54.3%	-10.1%
<b>Gain (-)/losses (+) on the divestment of businesses</b>																	n.m.	-96.9%	-99.6%	-98.0%	-98.8%	n.m.	-99.8%	-99.7%
Costs related to former business activities	1.0	1.2	2.2	2.2	4.4	4.5	6.7	8.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	n.m.	-96.9%	-99.6%	-98.0%	-98.8%	n.m.	-99.8%	-99.7%
<b>Total</b>	1.0	1.2	2.2	2.2	4.4	4.5	6.7	8.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
<b>Other one-time costs</b>																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
<b>Total</b>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
<b>Total adjustments</b>	8.9	15.0	23.9	20.3	44.1	15.0	35.3	59.1	11.4	-15.4	-4.0	18.5	14.5	3.3	21.8	17.9	28.0%	n.m.	n.m.	-8.8%	-67.1%	-77.8%	-38.2%	-69.8%
<b>EBITDA pre</b>	515.7	533.3	1 049.0	531.1	1 580.1	548.7	1 079.8	2 128.9	552.7	569.0	1 121.8	630.2	1 752.0	653.1	1 283.3	2 405.0	7.2%	6.7%	6.9%	18.7%	10.9%	19.0%	18.8%	13.0%

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.



**Detailed reconciliation - Performance Materials**

€ million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>95.2</b>	<b>99.5</b>	<b>194.8</b>	<b>98.1</b>	<b>292.8</b>	<b>14.3</b>	<b>112.3</b>	<b>307.1</b>	<b>116.3</b>	<b>-30.2</b>	<b>86.1</b>	<b>75.5</b>	<b>161.6</b>	<b>78.7</b>	<b>154.2</b>	<b>240.3</b>	22.1%	n.m.	-55.8%	-23.0%	-44.8%	451.5%	37.2%	-21.7%
Regular depreciation and amortization*	30.4	29.4	59.7	30.7	90.4	47.6	78.3	138.0	45.9	47.9	93.8	66.6	160.5	57.9	124.5	218.4	51.2%	63.3%	57.2%	116.8%	77.4%	21.6%	59.0%	58.2%
Amortization of purchased intangible assets	31.5	32.3	63.9	32.3	96.2	88.3	120.6	184.5	88.8	89.7	178.4	84.0	262.4	80.3	164.3	342.7	181.4%	177.4%	179.4%	159.9%	172.8%	-9.0%	36.2%	85.8%
Impairments**	0.0	0.0	0.0	8.3	8.3	-0.9	7.4	7.4	0.0	111.6	111.6	0.7	112.3	11.0	11.7	123.3	n.m.	n.m.	n.m.	-91.0%	>1.000%	n.m.	57.6%	>1.000%
<b>Total depreciation and amortization</b>	<b>61.9</b>	<b>61.7</b>	<b>123.6</b>	<b>71.3</b>	<b>194.9</b>	<b>135.1</b>	<b>206.4</b>	<b>330.0</b>	<b>134.7</b>	<b>249.2</b>	<b>383.9</b>	<b>151.4</b>	<b>535.2</b>	<b>149.2</b>	<b>300.6</b>	<b>684.4</b>	117.5%	304.1%	210.6%	112.2%	174.6%	10.5%	45.6%	107.4%
<b>EBITDA</b>	<b>157.1</b>	<b>161.2</b>	<b>318.3</b>	<b>169.4</b>	<b>487.7</b>	<b>149.3</b>	<b>318.7</b>	<b>637.0</b>	<b>251.0</b>	<b>219.0</b>	<b>470.0</b>	<b>226.8</b>	<b>696.9</b>	<b>227.9</b>	<b>454.7</b>	<b>924.7</b>	59.7%	35.9%	47.6%	33.9%	42.9%	52.6%	42.7%	45.2%
<b>Adjustments</b>																								
<b>Acquisition costs</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>81.8</b>	<b>81.8</b>	<b>81.8</b>	<b>19.0</b>	<b>0.5</b>	<b>19.4</b>	<b>0.1</b>	<b>19.5</b>	<b>1.0</b>	<b>1.1</b>	<b>20.5</b>	n.m.	n.m.	n.m.	n.m.	n.m.	-98.7%	-98.7%	-74.9%
<b>Restructuring costs</b>																								
Restructuring costs	34.1	26.3	60.5	0.9	61.3	-0.4	0.4	60.9	7.4	2.5	9.9	17.1	26.9	3.9	21.0	30.8	-78.4%	-90.6%	-83.7%	>1.000%	-56.1%	n.m.	>1.000%	-49.3%
<b>Total</b>	<b>34.1</b>	<b>26.3</b>	<b>60.5</b>	<b>0.9</b>	<b>61.3</b>	<b>-0.4</b>	<b>0.4</b>	<b>60.9</b>	<b>7.4</b>	<b>2.5</b>	<b>9.9</b>	<b>17.1</b>	<b>26.9</b>	<b>3.9</b>	<b>21.0</b>	<b>30.8</b>	-78.4%	-90.6%	-83.7%	>1.000%	-56.1%	n.m.	>1.000%	-49.3%
<b>Integration costs/IT costs</b>																								
Integration Cost	0.0	1.3	1.3	3.3	4.6	7.5	10.8	12.1	7.1	10.7	17.8	8.9	26.7	11.2	20.1	37.9	>1.000%	724.0%	>1.000%	171.3%	483.9%	49.3%	86.2%	213.7%
ERP/HR systems	1.3	1.5	2.8	3.9	6.7	4.7	8.6	11.4	1.1	5.6	6.6	0.8	7.4	2.1	2.9	9.5	-18.7%	269.8%	136.1%	-79.5%	10.5%	-55.8%	-66.7%	-16.6%
<b>Total</b>	<b>1.3</b>	<b>2.8</b>	<b>4.1</b>	<b>7.2</b>	<b>11.3</b>	<b>12.2</b>	<b>19.4</b>	<b>23.5</b>	<b>8.2</b>	<b>16.3</b>	<b>24.5</b>	<b>9.7</b>	<b>34.1</b>	<b>13.3</b>	<b>22.9</b>	<b>47.4</b>	525.0%	479.9%	494.2%	34.4%	201.7%	9.0%	18.4%	101.9%
<b>Gain (-)/losses (+) on the divestment of businesses</b>																								
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.1	0.0	0.1	0.6	0.6	0.0	0.6	0.7	n.m.	n.m.	n.m.	n.m.	n.m.	-73.1%	236.4%	266.2%
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.1</b>	<b>0.0</b>	<b>0.1</b>	<b>0.6</b>	<b>0.6</b>	<b>0.0</b>	<b>0.6</b>	<b>0.7</b>	n.m.	n.m.	n.m.	n.m.	n.m.	-73.1%	236.4%	266.2%
<b>Other one-time costs</b>																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%
<b>Total</b>	<b>0.0</b>	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%															
<b>Total adjustments</b>	<b>35.4</b>	<b>29.1</b>	<b>64.6</b>	<b>8.1</b>	<b>72.6</b>	<b>93.7</b>	<b>101.8</b>	<b>166.4</b>	<b>34.6</b>	<b>19.2</b>	<b>53.8</b>	<b>27.4</b>	<b>81.2</b>	<b>18.3</b>	<b>45.6</b>	<b>99.4</b>	-2.4%	-34.0%	-16.7%	239.2%	11.8%	-80.5%	-55.2%	-40.2%
<b>EBITDA pre</b>	<b>192.6</b>	<b>190.3</b>	<b>382.9</b>	<b>177.5</b>	<b>560.4</b>	<b>243.0</b>	<b>420.5</b>	<b>803.4</b>	<b>285.5</b>	<b>238.3</b>	<b>523.8</b>	<b>254.2</b>	<b>778.0</b>	<b>246.1</b>	<b>500.4</b>	<b>1 024.2</b>	48.3%	25.2%	36.8%	43.3%	38.8%	1.3%	19.0%	27.5%

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.



Detailed reconciliation - Corporate / Others

€ million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>-157.5</b>	<b>-147.9</b>	<b>-305.4</b>	<b>-131.4</b>	<b>-436.8</b>	<b>-180.2</b>	<b>-311.5</b>	<b>-617.0</b>	<b>-167.9</b>	<b>-133.5</b>	<b>-301.4</b>	<b>-133.1</b>	<b>-434.5</b>	<b>-223.5</b>	<b>-356.6</b>	<b>-658.0</b>	<b>6.6%</b>	<b>-9.7%</b>	<b>-1.3%</b>	<b>1.3%</b>	<b>-0.5%</b>	<b>24.0%</b>	<b>14.5%</b>	<b>6.6%</b>
Regular depreciation and amortization*	17.2	19.9	37.1	19.9	57.0	22.8	42.6	79.7	22.1	18.5	40.6	22.2	62.8	21.4	43.6	84.2	28.2%	-6.9%	9.4%	11.6%	10.2%	-5.8%	2.3%	5.6%
Amortization of purchased intangible assets	0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	-99.7%	n.m.	2.8%	79.2%	28.6%	>1.000%	>1.000%	>1.000%
Impairments**	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.4	0.0	0.2	0.2	0.0	0.2	0.0	0.0	0.2	n.m.	n.m.	n.m.	n.m.	n.m.	-100.0%	-100.0%	-62.7%
<b>Total depreciation and amortization</b>	<b>17.3</b>	<b>19.8</b>	<b>37.1</b>	<b>19.9</b>	<b>57.0</b>	<b>23.2</b>	<b>43.1</b>	<b>80.2</b>	<b>22.1</b>	<b>18.6</b>	<b>40.8</b>	<b>22.2</b>	<b>63.0</b>	<b>21.5</b>	<b>43.7</b>	<b>84.5</b>	27.5%	-5.6%	9.9%	11.6%	10.5%	-7.0%	1.6%	5.4%
<b>EBITDA</b>	<b>-140.2</b>	<b>-128.1</b>	<b>-268.3</b>	<b>-111.5</b>	<b>-379.8</b>	<b>-157.0</b>	<b>-268.5</b>	<b>-536.8</b>	<b>-145.8</b>	<b>-114.8</b>	<b>-260.6</b>	<b>-110.9</b>	<b>-371.5</b>	<b>-202.0</b>	<b>-312.9</b>	<b>-573.5</b>	4.0%	-10.4%	-2.9%	-0.5%	-2.2%	28.6%	16.5%	6.8%
<b>Adjustments</b>																								
<b>Acquisition costs</b>	<b>0.0</b>	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.															
<b>Restructuring costs</b>																								
Restructuring costs	25.9	4.3	30.2	2.0	32.2	-2.2	-0.2	30.0	4.3	5.2	9.5	-0.5	9.0	11.2	10.7	20.2	-83.4%	20.9%	-68.5%	n.m.	-72.0%	n.m.	n.m.	-32.6%
<b>Total</b>	<b>25.9</b>	<b>4.3</b>	<b>30.2</b>	<b>2.0</b>	<b>32.2</b>	<b>-2.2</b>	<b>-0.2</b>	<b>30.0</b>	<b>4.3</b>	<b>5.2</b>	<b>9.5</b>	<b>-0.5</b>	<b>9.0</b>	<b>11.2</b>	<b>10.7</b>	<b>20.2</b>	-83.4%	20.9%	-68.5%	n.m.	-72.0%	n.m.	n.m.	-32.6%
<b>IT project costs</b>																								
Integration Cost	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
ERP/HR systems	3.2	5.8	9.0	6.4	15.4	7.6	14.0	23.0	2.9	5.9	8.9	8.9	17.8	6.4	15.4	24.2	-8.1%	2.1%	-1.5%	39.8%	15.6%	-15.6%	9.6%	5.3%
<b>Total</b>	<b>3.2</b>	<b>5.9</b>	<b>9.1</b>	<b>6.5</b>	<b>15.6</b>	<b>7.6</b>	<b>14.1</b>	<b>23.2</b>	<b>3.0</b>	<b>5.9</b>	<b>8.9</b>	<b>8.9</b>	<b>17.8</b>	<b>6.4</b>	<b>15.4</b>	<b>24.2</b>	-6.7%	-0.5%	-2.7%	37.7%	14.1%	-15.4%	9.0%	4.4%
<b>Gain (-)/losses (+) on the divestment of businesses</b>																								
Costs related to former business activities	0.0	0.0	0.0	0.5	0.5	0.8	1.3	1.3	1.8	0.7	2.5	19.5	22.0	3.3	22.8	25.3	>1.000%	n.m.	n.m.	>1.000%	>1.000%	324.1%	>1.000%	>1.000%
<b>Total</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.5</b>	<b>0.5</b>	<b>0.8</b>	<b>1.3</b>	<b>1.3</b>	<b>1.8</b>	<b>0.7</b>	<b>2.5</b>	<b>19.5</b>	<b>22.0</b>	<b>3.3</b>	<b>22.8</b>	<b>25.3</b>	>1.000%	n.m.	n.m.	>1.000%	>1.000%	324.1%	>1.000%	>1.000%
<b>Other one-time costs</b>																								
Others	-0.7	5.8	5.1	4.4	9.5	3.6	8.0	13.1	7.6	-4.0	3.5	3.3	6.8	1.9	5.1	8.7	n.m.	n.m.	-30.9%	-25.3%	-28.3%	-48.1%	-35.5%	-33.7%
<b>Total</b>	<b>-0.7</b>	<b>5.8</b>	<b>5.1</b>	<b>4.4</b>	<b>9.5</b>	<b>3.6</b>	<b>8.0</b>	<b>13.1</b>	<b>7.6</b>	<b>-4.0</b>	<b>3.5</b>	<b>3.3</b>	<b>6.8</b>	<b>1.9</b>	<b>5.1</b>	<b>8.7</b>	n.m.	n.m.	-30.9%	-25.3%	-28.3%	-48.1%	-35.5%	-33.7%
<b>Total adjustments</b>	<b>28.4</b>	<b>16.0</b>	<b>44.4</b>	<b>13.4</b>	<b>57.8</b>	<b>9.8</b>	<b>23.2</b>	<b>67.6</b>	<b>16.7</b>	<b>7.7</b>	<b>24.4</b>	<b>31.2</b>	<b>55.6</b>	<b>22.8</b>	<b>54.0</b>	<b>78.4</b>	-41.2%	-51.9%	-45.0%	132.5%	-3.8%	133.2%	132.8%	16.0%
<b>EBITDA pre</b>	<b>-111.8</b>	<b>-112.1</b>	<b>-223.9</b>	<b>-98.1</b>	<b>-322.0</b>	<b>-147.2</b>	<b>-245.3</b>	<b>-469.2</b>	<b>-129.1</b>	<b>-107.2</b>	<b>-236.2</b>	<b>-79.7</b>	<b>-315.9</b>	<b>-179.1</b>	<b>-258.8</b>	<b>-495.1</b>	15.5%	-4.5%	5.5%	-18.7%	-1.9%	21.7%	5.5%	5.5%

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**

Group € million	2019								2020								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Financial result</b>	-112.6	-61.1	-173.7	-134.9	-308.5	-76.1	-210.9	-384.6	-98.5	-102.3	-200.7	-101.6	-302.3	-52.0	-153.6	-354.4	-12.5%	67.4%	15.6%	-24.6%	-2.0%	-31.6%	-27.2%	-7.9%
<b>Interest result</b>	-57.6	-55.5	-113.0	-85.4	-198.5	-93.8	-179.2	-292.3	-80.0	-72.8	-152.8	-74.0	-226.8	-61.8	-135.8	-288.6	39.0%	31.3%	35.2%	-13.4%	14.3%	-34.2%	-24.3%	-1.3%
Interest income	6.7	22.0	28.6	6.9	35.6	30.1	37.1	65.7	5.6	10.9	16.5	5.6	22.2	16.8	22.4	39.0	-15.2%	-50.4%	-42.2%	-18.8%	-37.7%	-44.3%	-39.5%	-40.7%
Interest expenses	-64.2	-77.5	-141.7	-92.4	-234.1	-123.9	-216.3	-358.0	-85.7	-83.7	-169.4	-79.6	-249.0	-78.5	-158.2	-327.6	33.4%	8.1%	19.6%	-13.8%	6.4%	-36.6%	-26.9%	-8.5%
<b>Result from financial investments</b>	-0.4	-0.5	-0.9	0.2	-0.6	0.5	0.7	-0.1	-0.1	-0.8	-0.9	1.0	0.1	1.5	2.5	1.6	-66.8%	68.0%	9.4%	348.4%	n.m.	199.7%	246.1%	n.m.
<b>Currency difference - financing</b>	-37.7	2.3	-35.4	3.1	-32.3	-0.7	2.5	-33.0	-6.0	5.2	-0.8	-3.4	-4.2	0.8	-2.6	-3.4	-84.0%	129.8%	-97.8%	n.m.	-87.1%	n.m.	n.m.	-89.8%
<b>Interest quota - pensions and other provi:</b>	-17.0	-6.8	-23.8	-52.8	-76.6	18.0	-34.8	-58.6	-12.3	-33.8	-46.2	-25.3	-71.4	7.5	-17.8	-64.0	-27.5%	397.3%	94.1%	-52.2%	-6.7%	-58.5%	-48.9%	9.2%
<b>Others</b>	0.0	-0.6	-0.6	0.0	-0.6	0.0	0.0	-0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	-100.0%	-100.0%	n.m.	-100.0%	-100.0%	-100.0%	-100.0%



